Business
Akili ADHD Study in The Lancet Digital Health
Akili ADHD Study in The Lancet Digital Health.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n RNS Number : 9768D\n PureTech Health PLC\n 25 February 2020\n \n \n \n \n 25 February 2020\n \n \n PureTech Health plc\n \n \n \n \n \n \n The Lancet Digital Health\n \n \n Publishes Akili \n \n \n AKL-T01 ADHD Pivotal Study Results \n \n \n \n \n \n \n First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD symptoms and functional impairments\n \n \n \n \n \n \n Study results suggest AKL-T01 could play an important role in the treatment of paediatric\n \n \n \n \n \n ADHD, directly targeting attention impairments\n \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\") is pleased to note that its affiliate, Akili, has \n \n \n published\n \n \n \n the \n results from its STARS-ADHD trial of AKL-T01, a digital therapeutic designed to improve attention in children with attention-deficit/hyperactivity disorder (ADHD), in The Lancet Digital Health journal. The publication represents the first presentation of complete results from the STARS-ADHD trial, a first-of-its-kind large, randomised, multi-centre, controlled study of the company's foundational technology and the first seminal trial in a series of recent and ongoing studies of the attentional treatment. Results show AKL-T01 improved both objective measures and parent observations of attention and functional impairments.\n \n \n Eric Elenko, PhD, chief innovation officer at PureTech, said: \"\n These complete results provide compelling insights and further validation for AKL-T01 for the treatment of inattention in children with ADHD. It also builds on the recently reported findings from Akili's STARS-ADHD Adjunctive study, which demonstrated additional promise for AKL-T01 as both a monotherapy and in combination with stimulant medications. It is exciting to see the mounting data for AKL-T01 which validates its potential.\" \n \n \n \n \n \n The STARS-ADHD study represents the company's largest clinical trial of AKL-T01 which has to-date been studied across five clinical trials including more than 600 children diagnosed with the disorder. \n Further researching the clinical implications of the attentional treatment on patients' daily lives, \n Akili recently \n \n \n \n conducted the STARS-ADHD Adjunctive study eval...